What precautions should a young athlete with hypertrophic obstructive cardiomyopathy follow?

Young Athletes with HOCM Should Be Disqualified from High-Intensity Competitive Sports

Young athletes diagnosed with hypertrophic obstructive cardiomyopathy (HOCM) should be restricted from competitive sports participation, as intense athletic competition acts as an independent, modifiable risk factor for sudden cardiac death, even in the absence of conventional risk markers 1.

Core Rationale for Sports Restriction

The fundamental issue is that competitive sports participation itself promotes ventricular tachycardia/ventricular fibrillation in HCM patients through:

• Physiological stresses from athletic training and competition
• Alterations in hydration, blood volume, and electrolytes
• Catecholamine surges during intense exertion
• Unpredictable instability of the myocardial substrate 1

HCM remains the most common cause of sudden death in young athletes, and the electrophysiological substrate is inherently unstable and unpredictable 1. Conventional risk stratification based on LV wall thickness or outflow tract gradients cannot reliably predict which athletes will experience sudden death during competition 1.

Specific Precautions and Restrictions

Sports Disqualification

• Disqualify from all high-intensity competitive sports (basketball, soccer, American football, etc.) 1
• This recommendation applies homogeneously across the broad HCM disease spectrum, regardless of phenotypic severity 1
• Young male athletes in high-risk sports face the greatest mortality risk 2

Permissible Activities

• Low-intensity recreational exercise may be considered after comprehensive evaluation 3
• Activities should avoid the physiological stresses of competitive training and competition

Mandatory Evaluations Before Any Exercise Clearance

• Comprehensive clinical evaluation including:
  • 12-lead ECG
  • Echocardiography (both resting and stress echocardiography to unmask exercise-induced LVOT obstruction) 4, 5
  • Cardiac MRI if indicated 6
• Sport-specific exercise testing to assess hemodynamic response and arrhythmia risk 7
• Extended duration ambulatory rhythm monitoring 6

Emerging Paradigm: Shared Decision-Making

While the 2015 guidelines 1 recommend conservative disqualification, the 2025 AHA/ACC statement 6 and recent case reports 7, 4 acknowledge that selected athletes may participate through rigorous shared decision-making, particularly:

Criteria for Consideration of Return to Play

• Comprehensive evaluation by sports cardiology and electrophysiology specialists
• Successful treatment of LVOT obstruction (e.g., mavacamten therapy showing complete resolution of gradients) 4
• ICD placement for secondary prevention if post-cardiac arrest 7
• Confirmation of rhythm stability with maximum-effort, sport-specific testing 6, 7
• Multidisciplinary agreement among family, clinicians, and athletic staff 7

Critical Caveats

• This individualized approach applies primarily to older athletes and those with controlled disease
• Adolescent and young adult male athletes remain highest risk 2
• The 2015 guidelines 1 explicitly state this may result in disqualifying some low-risk athletes who could potentially compete safely, but this conservative approach is necessary given the unpredictable nature of HCM

Genotype-Positive/Phenotype-Negative Athletes

Athletes with pathogenic sarcomere mutations but no LV hypertrophy present a unique scenario:

• Conversion to clinical HCM phenotype is unpredictable, occurring most often during adolescence (12-20 years) 1
• Once LV hypertrophy develops, the unstable electrophysiological substrate emerges 1
• Serial monitoring is essential if these athletes continue sports participation

Common Pitfalls to Avoid

1. Do not rely solely on resting echocardiography - exercise-induced LVOT obstruction may only manifest during stress testing 4, 5
2. Do not assume beta-blocker therapy provides adequate protection for competitive sports - medication does not eliminate the arrhythmogenic substrate 1
3. Do not apply adult risk stratification to young athletes - age itself is a risk factor, and adolescents face higher sudden death risk 2
4. Do not permit return to play based solely on ICD placement - the device treats arrhythmias but doesn't prevent them; comprehensive evaluation and shared decision-making are mandatory 6, 7

Treatment Considerations

• Mavacamten (cardiac myosin inhibitor) shows promise for eliminating LVOT obstruction and may facilitate return to play in highly selected cases 4, 8
• Surgical septal myectomy remains the gold standard for anatomical relief in refractory cases 9
• Beta-blockers provide symptomatic relief but may blunt exercise capacity benefits when combined with myosin inhibitors 8

The default position remains conservative disqualification from competitive sports, with rare exceptions only after exhaustive evaluation and explicit shared decision-making that acknowledges residual risk 1.